Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
Isolation and Analysis of Liquid Biopsy Markers using Microfluidics and a Liquid Handling Robot
Monday, 28 June 2021 at 15:00
Add to Calendar ▼2021-06-28 15:00:002021-06-28 16:00:00Europe/LondonIsolation and Analysis of Liquid Biopsy Markers using Microfluidics and a Liquid Handling RobotLab-on-a-Chip and Microfluidics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Liquid biopsies are generating great interest within the medical community due to the simplicity for securing important biomarkers to manage complex diseases, such as many of the cancer-related diseases. We are developing a suite of novel microfluidic devices that can process clinical samples directly and efficiently search for a variety of disease-associated liquid biopsy markers, such as circulating tumor cells (CTCs), cell free DNA (cfDNA), and extracellular vesicles (EVs). The microfluidic chips are made in plastics via injection molding and designed to optimize recovery and purity of each of the aforementioned biomarkers. The challenge with microfluidics is the need for attaching connector tubing to the microfluidic and using syringe pumps to fluidically operate the chips. We have developed liquid handling robots to automatically operate microchips and do so in a high throughput and automated fashion, appropriate for use in centralized clinical testing laboratories. The robots operate using pipet tips and do not require connector tubing reducing chip production costs. The robotic platforms were used along with specifically designed chips for analysis of each of the liquid biopsy markers. Examples of using the system for supporting large clinical studies will be discussed, such as CTCs for discovering new therapies for pancreatic cancer, cell free DNA genotyping for breast cancer, and EVs for patient stratification in ovarian and breast cancers.
Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics Europe 2021Lab-on-a-Chip and Microfluidics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2021-06-28 15:00:002021-06-28 16:00:00Europe/LondonIsolation and Analysis of Liquid Biopsy Markers using Microfluidics and a Liquid Handling RobotLab-on-a-Chip and Microfluidics Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
